Clinical Potential of Eosinophil-Derived Neurotoxin in Asthma Management.
Asthma
Biomarker
Eosinophil-derived neurotoxin
Monitoring
Type 2 inflammation
Journal
The journal of allergy and clinical immunology. In practice
ISSN: 2213-2201
Titre abrégé: J Allergy Clin Immunol Pract
Pays: United States
ID NLM: 101597220
Informations de publication
Date de publication:
03 2023
03 2023
Historique:
received:
29
06
2022
revised:
24
11
2022
accepted:
28
11
2022
pubmed:
30
12
2022
medline:
14
3
2023
entrez:
29
12
2022
Statut:
ppublish
Résumé
The assessment and management of patients with asthma is challenging because of the complexity of the underlying inflammatory mechanisms and heterogeneity of their clinical presentation. Optimizing disease management requires therapy individualization that should rely on reliable biomarkers to unravel the phenotypes and endotypes of asthma. The secretory activity and turnover of eosinophils, as assessed by measuring eosinophil-derived proteins, may provide an accurate and complementary tool that mirrors the eosinophil activation status. Emerging evidence suggests that eosinophil-derived neurotoxin has considerable potential as a precision medicine biomarker. In this review, we explore the suitability of eosinophil-derived neurotoxin as a biomarker in asthma management, with particular emphasis on its clinical significance in the management of both pediatric and adult populations.
Identifiants
pubmed: 36581068
pii: S2213-2198(22)01319-8
doi: 10.1016/j.jaip.2022.11.046
pii:
doi:
Substances chimiques
Eosinophil-Derived Neurotoxin
EC 3.1.-
Biomarkers
0
Types de publication
Review
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
750-761Informations de copyright
Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved.